Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C

Alessio Aghemo, Maria Grazia Rumi, Massimo Colombo

Research output: Contribution to journalArticlepeer-review


Chronic infection with HCV has an estimated prevalence of 1.6-2.0% worldwide and is a major cause of liver-related death. The first attempts to halt the progression of infection relied on the empirical use of interferon (IFN), a naturally occurring cytokine that is implicated in antiviral innate immunity. The first studies of this treatment in the early 1990s, however, led to disappointing response rates. These response rates subsequently improved with the empirical addition of the guanosine analog ribavirin to the treatment regimen. To improve the effectiveness and tolerability of the three times per week therapeutic schedule of IFN, two forms of pegylated interferon (PEG-IFN) were developed in the early 2000s-PEG-IFN-α2a and PEG-IFN-α2b. These two compounds differ markedly in size, structure, site of attachment of the polyethylene glycol moiety and type of bond involved in pegylation, which ultimately confer different pharmacokinetics and biological activity. Unsurprisingly, researchers question whether the two PEG-IFNs also differ in clinical effectiveness, but the re-analysis of restrospective studies and the results of three head-to-head studies have left this issue open. We have, therefore, scrutinized the design and conduct of all available studies to unravel the reasons behind the therapeutic differences between PEG-IFN-α2a and PEG-IFN-α2b.

Original languageEnglish
Pages (from-to)485-494
Number of pages10
JournalNature Reviews Gastroenterology and Hepatology
Issue number9
Publication statusPublished - Sep 2010

ASJC Scopus subject areas

  • Medicine(all)
  • Gastroenterology
  • Hepatology

Fingerprint Dive into the research topics of 'Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C'. Together they form a unique fingerprint.

Cite this